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ttp://dx.doi.org/10.1016/j.ajpath.2014.07.004Activated microglia are associated with amyloid plaques in transgenic mouse models of cerebral
amyloidosis and in human Alzheimer disease; yet, their implication in Alzheimer disease pathogenesis
remains unclear. It has been suggested that microglia play dual roles depending on the context of
activation, contributing negatively to disease pathogenesis by secreting proinﬂammatory innate
cytokines or performing a beneﬁcial role via phagocytosis of amyloid beta (Ab) deposits. Toll-like
receptors, most of which signal through the adaptor protein myeloid differentiation factor 88 (MyD88),
have been suggested as candidate Ab innate pattern recognition receptors. It was recently reported
that MyD88 deﬁciency reduced brain amyloid pathology and microglial activation. To assess a putative
role of MyD88 in cerebral amyloidosis and glial activation in APPswe/PS1DE9 (APP/PS1) mice, we
crossed MyD88-deﬁcient (MyD88/) mice with APP/PS1 mice, interbred ﬁrst ﬁlial offspring, and
studied APP/PS1 MyD88þ/þ, APP/PS1 MyD88þ/, and APP/PS1 MyD88/ cohorts. Biochemical analysis
of detergent-soluble and detergent-insoluble Ab1-40 or Ab1-42 in brain homogenates did not reveal
signiﬁcant between-group differences. Furthermore, no signiﬁcant differences were observed on am-
yloid plaque load or soluble ﬁbrillar Ab by quantitative immunohistochemical analysis. In addition,
neither activated microglia nor astrocytes differed among the three groups. These data suggest that
MyD88 signaling is dispensable for Ab-induced glial activation and does not signiﬁcantly affect the
nature or extent of cerebral b-amyloidosis in APP/PS1 mice. (Am J Pathol 2014, 184: 2855e2861;
http://dx.doi.org/10.1016/j.ajpath.2014.07.004)Supported by NIH/National Institute of Neurological Disorders and Stroke
grant R01 NS076794-01 (T.T.); Alzheimer’s Association Zenith Award ZEN-
10-174633 (T.T.); American Federation of Aging Research/Ellison Medical
Foundation JulieMartinMid-Career Award in Aging ResearchM11472 (T.T.);
and faculty start-up funds from the Zilkha Neurogenetic Institute (T.T.).
Disclosures: None declared.Alzheimer disease (AD) is an insidious public health threat
characterized by deposition of b-amyloid as senile plaques,
formation of neuroﬁbrillary tangles, and large-scale cortical
neuronal loss leading to dementia. In addition to these patho-
gnomonic features of the disease, AD patients exhibit low-level
chronic neuroinﬂammation. This is hallmarked by the spatial
and temporal occurrence of activated microglia with amyloid
beta (Ab) deposits. Yet, the mechanisms by which microglia
recognize and respond to Ab accumulation remain unclear.
Current evidence suggests that there are varied forms of acti-
vatedmicroglia inAD, someofwhich are detrimental and others
beneﬁcial.1 Because microglial activation is a complex contin-
uum of varied responses,2 it stands to reason that a wide array of
immunemolecules may orchestrate microglial responses to Ab.
Ultimately, a clearer understanding of the pathways leading to
beneﬁcial microglial responses and clearance of misfolded
proteins could open new avenues for AD treatment.stigative Pathology.
.Numerous recent studies have proposed that Toll-like re-
ceptors (TLRs) play a role in the microglial response to Ab
and, more speciﬁcally, that aggregated Ab can activate
microglia via TLRs.3e11 Most TLRs (except TLR3) signal
through the adaptor protein myeloid differentiation factor 88
(MyD88), suggesting that it may play an important role in
microglial activation in response to cerebral amyloid accu-
mulation. To test this possibility, two recent studies crossed
MyD88 knockout mice with APP/PS1 mouse models of ce-
rebral amyloid deposition and examined effects on cognitive
deﬁcits and AD-like pathology. In one study, it was reported
Weitz et althat MyD88 deﬁciency of the doubly transgenic APPswe/
PS1dE9 mouse reduced cerebral amyloid pathology and
microglial activation and decreased expression of CX3CR1 in
10-month-old animals.12 Lim and coworkers12 suggested that
inhibiting MyD88-associated TLR signaling would alter the
microglial activation state, and they reported less cerebral
amyloid deposition in this cross. However, their ﬁndings were
perplexing given previous reports showing that activation of
TLRs leads to decreased amyloid load and increased Ab
phagocytosis, leading to the hypothesis thatMyD88 deﬁciency
would either cause buildup of amyloid or have no effect on
amyloid levels in APP/PS1 mice.4,6,11,13e15 Another recent
study published ﬁndings more consistent with this hypothesis,
demonstrating that APPswe/PS1A246Emice heterozygous for
MyD88 had accelerated spatial learning and memory deﬁcits
and increased levels of soluble Ab oligomers. These results led
the authors to conclude that MyD88-mediated activation of
microglia was protective in the context of cerebral amyloid
deposition.16 In an attempt to clarify the uncertainty sur-
rounding this critical question, we crossed APPswe/PS1dE9
(APP/PS1) mice with MyD88 knockout (MyD88/) mice
(both on a C57BL/6 background) and analyzed APP/PS1
MyD88þ/þ, APP/PS1 MyD88þ/, and APP/PS1 MyD88/
cohorts for Alzheimer-like pathology at 15 months of age.Materials and Methods
Animals
MyD88 knockout mice (MyD88/mice) in a mixed C57BL/
6  129 background were gifted by Shizuo Akira (Osaka
University, Osaka, Japan) and were backcrossed to C57BL/6
mice for >10 generations. B6.Cg-Tg(APPswe,PSEN1dE9)
85Dbo/J mice (APP/PS1 mice) were purchased from The
Jackson Laboratory (Bar Harbor, ME) and were crossed with
MyD88/ mice to generate APP/PS1 MyD88þ/ offspring.
First ﬁlial APP/PS1 MyD88þ/ mice were then crossed with
MyD88/ mice. For this study, these second ﬁlial offspring
(mouse groups: APP/PS1 MyD88þ/þ, n Z 9; APP/PS1
MyD88þ/, n Z 9; and APP/PS1 MyD88/, n Z 6) were
aged for 15 months, at which point they were euthanized for
analysis of AD-like pathology. All the animal protocols used
for this study were approved by the Yale University Institu-
tional Animal Care and Use Committee (New Haven, CT).Tissue Isolation and Preparation
Animals were deeply anesthetized with 2% to 4% isoﬂurane
and were perfused intracardially with sterile ice-cold
phosphate-buffered saline. Brains were extracted and quar-
tered. The two front quarters were snap frozen for protein
extraction and biochemical analysis, and the rear quarters
were ﬁxed in 4% paraformaldehyde overnight for subse-
quent OCT and parafﬁn embedding, according to previously
published methods.17,182856Biochemical Analysis
We performed biochemical analysis of Ab peptides accord-
ing to a two-step extraction method.17,19 Brieﬂy, one front
brain quarter was randomly selected, weighed, and homog-
enized with 500 mL of ice-cold lysis buffer and centrifuged at
15,000  g for 15 minutes. The supernatant (triton-soluble
fraction) was removed and the pellet was treated with 10
volume of 5 mol/L guanidine HCl (pH 8.0) overnight to
extract detergent-insoluble isoforms. Ab species were
quantiﬁed in detergent-soluble and detergent-insoluble frac-
tions using Ab1-40,42 enzyme-linked immunosorbent assay
(ELISA) kits (Invitrogen, Carlsbad, CA), with no dilution for
triton-soluble fractions and a 1:500 dilution for guanidine
HCl fractions. Total protein levels were determined by
bicinchoninic acid protein assay (Thermo Fisher Scientiﬁc,
Rockford, IL) and were used to normalize Ab ELISA results.
Immunohistochemical Analysis, Microscopy, and
Quantitative Image Analysis
Coronal sections (10 mm) were sliced at 50-mm intervals
using a Leica RM2125 microtome (Leica Microsystems,
Buffalo Grove, IL) and were mounted on glass slides. Sec-
tions were then dewaxed in xylenes, hydrated in a graded
series of ethanol, and boiled in antigen retrieval buffer
(Dako, Glostrup, Denmark) for 30 minutes. Sections were
then blocked with serum-free protein block (Dako) and hy-
bridized overnight at 4C with one or more of the following
primary antibodies: Iba1 (dilution 1:250; Wako Chemicals
USA Inc., Richmond, VA); 4G8 (dilution 1:200; Covance
Inc., Princeton, NJ); OC-oligomer conformation antibody
[dilution 1:1000; a gift from Dr. Charles G. Glabe (Uni-
versity of California, Irvine, CA)]; CD45 (Abcam Plc.,
Cambridge, UK), and glial ﬁbrillary acidic protein (dilution
1:2000; Dako). Sections were then washed and incubated
with the appropriate ﬂuorophore-conjugated secondary an-
tibodies (dilution 1:200; Invitrogen). For amyloid burden,
sections were directly stained with 1% Thioﬂavin S (ThioS;
Sigma-Aldrich, St. Louis, MO) according to standard prac-
tice. All the sections were coverslipped with ProLong Gold
mounting medium (Dako) before imaging. Stained sections
were viewed and imaged using a Zeiss Axio Imager M2 with
an attached ApoTome camera (Carl Zeiss Microscopy, Jena,
Germany). Quantitative histologic analysis was performed
using previously published methods.17,18 Images of four 10-
mm sections (150 mm apart) through each anatomical region
of interest (hippocampus or cortical areas) were captured and
image analysis was performed using ImageJ version 1.45
(NIH, Bethesda, MD). For each image, a threshold optical
density was obtained that discriminated staining from
background, and each ﬁeld was manually edited to eliminate
artifacts. For b-amyloid and ThioS burden, along with
astrocytosis and microgliosis analyses, data are reported as
integrated densities. Similar analysis using the percentage of
immunolabeled area captured (positive pixels) divided byajp.amjpathol.org - The American Journal of Pathology
Figure 1 MyD88 deﬁciency does not alter amyloid beta (Ab) oligomer
levels in APP/PS1 mice. Two-stepeextracted brain homogenates from APP/
PS1 MyD88þ/þ (white bars), APP/PS1 MyD88þ/ (gray bars), and APP/PS1
MyD88/ (black bars) mice were assayed for triton-soluble human Ab1e40
(A) and Ab1e42 (B) or for 5 mol/L guanidine HClesoluble human Ab1e40 (C)
and Ab1e42 (D). All the animals from each group were included in each
analysis (APP/PS1 MyD88þ/þ, nZ 9; APP/PS1 MyD88þ/, nZ 9; and APP/
PS1 MyD88/, n Z 6). Bars represent means  SEM.
MyD88 and Alzheimer-Like Diseasethe full area captured (total pixels) gave comparable results.
Each immunohistochemical analysis was performed by a
single examiner (T.M.W., D.G., or K.R.-Z.) in a blinded
manner.
Immunoblotting and Densitometric Analysis
One front brain quarter was randomly assigned to homoge-
nization in ice-cold lysis buffer and was centrifuged at
15,000 g for 15 minutes. The supernatant was collected for
Western blot analysis. Protein concentrations were deter-
mined by bicinchoninic acid protein assay, and 25 to 50 mg of
protein was electrophoresed on Mini-PROTEAN TGX gels
(Bio-Rad Laboratories, Hercules, CA) and transferred to
nitrocellulose membranes using the Trans-Blot Turbo system
(Bio-Rad Laboratories). Membranes were blocked with
blocking buffer (Tris-buffered saline þ 0.1% Tween-
20 þ 5% nonfat dried milk) for 30 minutes and were then
incubated overnight at 4Cwith one of the following primary
antibodies: 22C11 (Millipore, Billerica, MA), 6E10 (Chem-
icon, Temecula, CA), or CX3CR1 (Santa Cruz Biotech-
nology, Santa Cruz, CA). Membranes were washed and
hybridized with the appropriate horseradish peroxidase
conjugated secondary antibody (dilution 1:3000; Vector
Laboratories, Burlingame, CA) for 1 hour at room tempera-
ture in blocking buffer. Proteins were visualized using
SuperSignal West Pico chemiluminescent substrate (Thermo
Fisher Scientiﬁc). The membranes were stripped and repro-
bed with antibody to actin (diluted 1:1000; Millipore). The
resulting protein bands were scanned using an Epson
Perfection V750 Pro scanner (Epson Electronics, Schaum-
burg, IL), and the integrated density of each protein band was
determined using ImageJ version 1.45. To normalize for
protein loading, the integrated density of each band was
divided by the integrated density of the actin band in the same
lane from the same membrane.
Statistical Analysis
All the experiments were performed by an examiner blinded
to sample and subject identities (T.M.W., D.G., or K.R.-Z.),
and code was not broken until the analyses were completed.
Because signiﬁcant differences were not detected between
males and females, both sexes were combined within groups.
Data are presented as means  1 SEM. For single mean
comparisons, the Levene test for equality of the variance and
then Student’s t-test for independent samples were per-
formed. In instances of multiple mean comparisons, one-way
analysis of variance was used, followed by post hoc com-
parison of the means using Bonferroni or Dunnett T3
methods (where appropriateness was determined by the
Levene test for equality of the variance). P < 0.05 was
considered signiﬁcant. All the analyses were performed using
GraphPad Prism 6 (GraphPad Software Inc., La Jolla, CA).
Power analyses were conducted using Power and Precision
software version 2 (Biostat, Englewood, NJ).The American Journal of Pathology - ajp.amjpathol.orgResults
Cerebral b-Amyloidosis
If MyD88 played a signiﬁcant role in the microglial
response to Ab, then MyD88 deﬁciency might signiﬁcantly
alter b-amyloidosis in brains of APP/PS1 mice. However,
biochemical analysis of human Ab1-40 and Ab1-42 in triton-
soluble and triton-insoluble brain extracts and 5 mol/L
guanidine HClesoluble extracts from aged APP/PS1
MyD88þ/þ, APP/PS1 MyD88þ/, and APP/PS1 MyD88/
mice revealed no signiﬁcant between-group differences in
either Ab species (Figure 1). To assess the effect of
knocking out MyD88 on amyloid plaque load in APP/PS1
mice, we performed a quantitative histologic analysis of
diffuse amyloid plaques after staining with human Ab
antibody (4G8). The results did not reveal signiﬁcant dif-
ferences in amyloid burden among the three groups of mice
in three brain regions classically associated with AD in
humans: the cingulate cortex, hippocampus, and entorhinal
cortex (Figure 2, A and B). In addition, we examined levels
of soluble oligomeric ﬁbrillar Ab using a conformation-
speciﬁc OC antibody20,21 and also analyzed ﬁbrillar amy-
loid plaques by ThioS staining. Complementing the data
presented previously herein, neither immunostaining with
OC antibody nor staining with ThioS revealed signiﬁcant
between-genotype differences in any of the three brain re-
gions examined (Figure 2, CeE).Microgliosis and Astrogliosis
Progressive amyloid accumulation in APP/PS1 mice is
associated with neuroinﬂammation, typically earmarked by2857
Figure 2 b-Amyloid and soluble ﬁbrillar amy-
loid beta (Ab) burden are unchanged in APP/PS1
mice deﬁcient for MyD88. A: Photomicrographs of
4G8 and Iba1 staining from APP/PS1 MyD88þ/þ
and APP/PS1 MyD88/ brain sections from the
cingulate cortex (CC) and hippocampus (HC). B:
Quantitative histologic analysis (four sections per
mouse) of 4G8 staining in the CC, HC, and ento-
rhinal cortex (EC) of APP/PS1 MyD88þ/þ (white
bars), APP/PS1 MyD88þ/ (gray bars), and APP/
PS1 MyD88/ (black bars) mice. C and D: Pho-
tomicrographs of soluble ﬁbrillar Ab antibody (OC)
staining of APP/PS1 MyD88þ/þ and APP/PS1
MyD88/ brain sections (C) and quantitative
histologic analysis of OC staining in all three ge-
notypes (D). E: Quantitative histologic analysis of
ThioS staining in the CC, HC, and EC of all three
genotypes. Bars represent means  SEM. Scale
bars: 50 mm.
Weitz et alplaque-associated reactive microglia and astroglia. Based on
the present results indicating no differences in Ab/b-amy-
loid abundance between MyD88-sufﬁcient and MyD88-
deﬁcient animals, we did not expect differences in gliosis
among the three genotypes. However, it could still be
possible that microglia deﬁcient in MyD88 were altered in
number or activation status in response to, but not affecting,
cerebral Ab load. On quantitative analysis of Iba1 staining
for activated microglia in cingulate cortex, hippocampus,
and entorhinal cortex, the percentage of area covered by
Iba1þ cells did not differ among the three genotypes, indi-
cating that MyD88 deﬁciency did not affect microgliosis in
APP/PS1 mice (Figure 3, A and B). Moreover, quantitative
analysis for CD45 immunoreactivity, a common marker for
activated microglia, and glial ﬁbrillary acidic protein, a
marker for reactive astrocytes, did not produce between-
genotype differences in the three brain regions surveyed
(Figure 3, C and D).APP Processing
To control for the possibility that MyD88 deﬁciency altered
amyloid precursor protein (APP) expression or APP meta-
bolism, biochemical analyses were performed. As expected,
the results indicated that APP processing was unaltered
among the three genotypes of mice. Furthermore, the
amyloidogenic APP b-C terminal fragment also remained2858unchanged (Figure 4, AeC), indicating that MyD88 deﬁ-
ciency was unable to alter amyloidogenic APP metabolism.
Fractalkine Receptor Expression
Several studies have shown a role for CX3CR1, the frac-
talkine receptor, in the context of microglial responses to
cerebral amyloidosis.22,23 In addition, a recent report
showed decreased CX3CR1 expression in MyD88-deﬁcient
mouse models of cerebral amyloid deposition.12 To elimi-
nate the possibility that the microglia in the cohort of
MyD88-deﬁcient animals had altered CX3CR1 expression,
we performed Western blot analysis on brain homogenates
from all three genotypes using CX3CR1 antibody, followed
by densitometric analysis. However, no signiﬁcant between-
group differences were detected (Figure 4, A and D), indi-
cating that MyD88 deﬁciency had no obvious effect on
microglial CX3CR1 expression in APP/PS1 mice.
Discussion
Although the innate immune response is thought to play a
central role in AD progression, the speciﬁc role of microglia
in this process is still uncertain. There are multiple studies
in vivo and in vitro suggesting that TLRs play a role in
cerebral Ab clearance.4,6,7,24e26 For example, a recent
study examining the effects of knocking out Tlr2 inajp.amjpathol.org - The American Journal of Pathology
Figure 3 MyD88 deﬁciency does not alter
gliosis in APP/PS1mice. A: Images of glial ﬁbrillary
acidic protein (GFAP) and CD45 staining for acti-
vated microglia in MyD88-sufﬁcient (MyD88þ/þ)
and MyD88-deﬁcient (MyD88/) APP/PS1 mice.
BeD: Quantitative analysis of Iba1 (B), CD45 (C),
and activated astroglia (GFAP) (D) staining in the
cingulate cortex (CC), hippocampus (HC), and en-
torhinal cortex (EC) from APP/PS1 MyD88þ/þ
(white bars), APP/PS1 MyD88þ/ (gray bars), and
APP/PS1 MyD88/ (black bars) mice. Bars repre-
sent means  SEM. Scale barZ 50 mm.
MyD88 and Alzheimer-Like DiseaseAPPswe/PS1(A246E) mice found decreased amyloid plaque
burden and increased soluble Ab1-42.
7 In another study,
APPswe/PS1dE9 mice homozygous for a destructive mu-
tation in Tlr4 (TlrLps-d/TlrLps-d) were found to have increased
diffuse and ﬁbrillar Ab deposits as well as increased soluble
and insoluble Ab abundance.6
Although mounting evidence points to TLRs impacting
AD-like pathology in mouse models and Ab-inducedFigure 4 Amyloid precursor protein (APP) processing and fractalkine
receptor expression are not altered in APP/PS1 mice deﬁcient for MyD88. A:
Representative Western blots of brain homogenates from APP/PS1 MyD88þ/þ
(white bars), APP/PS1 MyD88þ/ (gray bars), and APP/PS1 MyD88/ (black
bars) mice reacted with 22C11 antibody (against APP), 6E10 [against b-C
terminal fragment (b-CTF)], CX3CR1 (fractalkine receptor), and actin (for
normalization) antibodies. BeD: Densitometric analyses are shown for
22C11 (APP) (B), 6E10 (b-CTF) (C), and CX3CR1 (D) antibodies. Integrated
densities of bands from each mouse were normalized to actin. Bars represent
means  SEM. a.u., arbitrary units.
The American Journal of Pathology - ajp.amjpathol.orgneurotoxicity in vitro, studies examining the role of
MyD88 in microglial responses to Ab have been contra-
dictory. For example, MyD88-deﬁcient APPswe/PS1dE9
and APPswe/PS1(A246E) mice with reduced MyD88
expression have previously been reported to have reduced
amyloid plaque burden Yet, APPswe/PS1(A246E) mice
with attenuated MyD88 expression were also found to
have increased levels of soluble Ab and accelerated spatial
memory deﬁcit in the T-water maze,16 whereas MyD88-
deﬁcient APPswe/PS1dE9 mice had decreased soluble Ab
and improved spatial learning in the Morris water
maze.12,27 These conﬂicting results raise at least two
different scenarios: signaling through TLRs via MyD88 in
response to increasing Ab burden results in detrimental
inﬂammation that ultimately aggravates disease; and
signaling through MyD88 is protective against AD-like
disease. To clarify this, we crossed APPswe/PS1dE9
mice with MyD88 knockout mice and examined aged
offspring. The results indicate that MyD88-deﬁcient
APPswe/PS1dE9 mice are not signiﬁcantly different from
MyD88-sufﬁcient APPswe/PS1dE9 mice on measures of
AD-like pathology. Thus, in contrast to the two other re-
ports, we conclude that signaling through TLRs via
MyD88 does not signiﬁcantly affect the nature or extent of
AD-like pathology in aged APP/PS1 mouse brains.
The differing results between the present study and pre-
vious reports could be accounted for by differences in the
transgenic lines used and/or breeding anomalies. Whereas
Lim et al12 used the same APP/PS1 transgenic and MyD88-
deﬁcient mouse lines on a pure C57BL/6 background as
reported herein, another previous study used a different line
of transgenic mice [APPswe/PS1(A246E)],16 making it
difﬁcult to directly compare these results to theirs. In
addition, both of the aforementioned studies had difﬁculty2859
Weitz et alproducing APP/PS1 MyD88/ animals from their crosses
of MyD88/ mice with APP/PS1 animals, a problem that
we did not encounter in this report. Another difference be-
tween these studies and ours is the age of the mice. Previous
reports showed that MyD88 deﬁciency impacted AD-like
pathology in APP/PS1 transgenic mice at 9 months of
age.12,16 According to the present results, if there is such an
effect, it is quantitatively minor at 15 months of age. One
explanation is that MyD88 deﬁciency slows amyloid
buildup during the early stages of amyloidosis in APP/PS1
mice and that at some point the amyloid burden reaches a
threshold that MyD88-deﬁcient microglia are unable to
mitigate. In addition, differences in tissue dissection, sam-
pling, and extraction may account for some of the discrep-
ancies between reports. It is also important to consider
statistical power to detect a signiﬁcant difference, if one
were, in fact, present. In this regard, a formal statistical
power analysis was conducted and revealed that this study
has 80% power to detect a 40% difference in plaque load at
a signiﬁcance level of 0.05. Furthermore, note that Lim
et al12 used fewer mice in their study (nZ 6 per group), and
they were able to detect signiﬁcant differences (effect size,
30% to 40%; P < 0.05) between genotypes in amyloid load,
indicating that sizable differences can be detected between
groups with these numbers. Last, it deserves mentioning that
the present methods have been validated17,18 and have
produced signiﬁcant differences in plaque load and gliosis
in several other experimental studies on mouse models of
cerebral amyloidosis. Whatever the reason for discrepancy,
if MyD88 deﬁciency does not affect amyloidosis in aged
APP/PS1 mice, it is not likely to be clinically relevant.
It is becoming clear that a wide array of activated
microglial phenotypes exist, some of which are detrimental
and others beneﬁcial, in the context of AD. In addition, the
nature of the stimulus can largely affect the type of micro-
glial response that is mounted.1,2 Based on these results, we
conclude that blocking proinﬂammatory innate immune re-
sponses by making APP/PS1 mice deﬁcient forMyD88 does
not signiﬁcantly affect AD-like pathology. However, reba-
lancing inﬂammation by blocking key immunosuppressive
factors may be more effective at remediating AD-like pa-
thology. For example, the present group previously showed
that genetic ablation of innate immune TGF-beSmad 2/3
signaling leads to resolution of cerebral amyloidosis, which
does not come at the cost of damaging neuroinﬂammation.18
Other studies currently ongoing in the Town laboratory also
indicate that boosting proinﬂammatory responses can reduce
the extent of b-amyloidosis in APP/PS1 mice.Acknowledgments
We thank Ken-ichiro Fukuchi (University of Illinois College
of Medicine, Chicago, IL) for helpful discussions, Melanie
Das (Cedars-Sinai Medical Center, Los Angeles, CA) for
technical assistance with immunostaining and ELISA, and2860Dr. Charles G. Glabe (University of California, Irvine, CA)
for the gift of OC-oligomer conformation antibody.References
1. Weitz TM, Town T: Microglia in Alzheimer’s disease: it’s all about
context. Int J Alzheimers Dis 2012, 2012:314185
2. Town T, Nikolic V, Tan J: The microglial “activation” continuum:
from innate to adaptive responses. J Neuroinﬂammation 2005, 2:24
3. Lotz M, Ebert S, Esselmann H, Iliev AI, Prinz M, Wiazewicz N,
Wiltfang J, Gerber J, Nau R: Amyloid beta peptide 1-40 enhances the
action of Toll-like receptor-2 and -4 agonists but antagonizes Toll-like
receptor-9-induced inﬂammation in primary mouse microglial cell
cultures. J Neurochem 2005, 94:289e298
4. Tahara K, Kim HD, Jin JJ, Maxwell JA, Li L, Fukuchi K: Role of toll-
like receptor signaling in Abeta uptake and clearance. Brain 2006,
129(Pt 11):3006e3019
5. Balistreri CR, Grimaldi MP, Chiappelli M, Licastro F, Castiglia L,
Listì F, Vasto S, Lio D, Caruso C, Candore G: Association between the
polymorphisms of TLR4 and CD14 genes and Alzheimer’s disease.
Curr Pharm Des 2008, 14:2672e2677
6. Richard KL, Filali M, Préfontaine P, Rivest S: Toll-like receptor 2 acts
as a natural innate immune receptor to clear amyloid beta 1-42 and
delay the cognitive decline in a mouse model of Alzheimer’s disease.
J Neurosci 2008, 28:5784e5793
7. Jana M, Palencia CA, Pahan K: Fibrillar amyloid-beta peptides activate
microglia via TLR2: implications for Alzheimer’s disease. J Immunol
2008, 181:7254e7262
8. Frank S, Copanaki E, Burbach GJ, Müller UC, Deller T: Differential
regulation of toll-like receptor mRNAs in amyloid plaque-associated
brain tissue of aged APP23 transgenic mice. Neurosci Lett 2009,
453:41e44
9. Reed-Geaghan EG, Savage JC, Hise AG, Landreth GE: CD14 and toll-
like receptors 2 and 4 are required for ﬁbrillar A{beta}-stimulated
microglial activation. J Neurosci 2009, 29:11982e11992
10. Scholtzova H, Kascsak RJ, Bates KA, Boutajangout A, Kerr DJ,
Meeker HC, Mehta PD, Spinner DS, Wisniewski T: Induction of toll-
like receptor 9 signaling as a method for ameliorating Alzheimer’s
disease-related pathology. J Neurosci 2009, 29:1846e1854
11. Song M, Jin J, Lim JE, Kou J, Pattanayak A, Rehman JA, Kim HD,
Tahara K, Lalonde R, Fukuchi K: TLR4 mutation reduces microglial
activation, increases Ab deposits and exacerbates cognitive deﬁcits in a
mouse model of Alzheimer’s disease. J Neuroinﬂammation 2011, 8:92
12. Lim JE, Kou J, Song M, Pattanayak A, Jin J, Lalonde R, Fukuchi K:
MyD88 deﬁciency ameliorates b-amyloidosis in an animal model of
Alzheimer’s disease. Am J Pathol 2011, 179:1095e1103
13. Doi Y, Mizuno T, Maki Y, Jin S, Mizoguchi H, Ikeyama M, Doi M,
Michikawa M, Takeuchi H, Suzumura A: Microglia activated with the
toll-like receptor 9 ligand CpG attenuate oligomeric amyloid beta-
neurotoxicity in in vitro and in vivo models of Alzheimer’s disease.
Am J Pathol 2009, 175:2121e2132
14. Tahara K, Kim HD, Jin JJ, Maxwell JA, Li L, Fukuchi K, Iribarren P,
Chen K, Hu J, Gong W, Cho EH, Lockett S, Uranchimeg B, Wang JM:
CpG-containing oligodeoxynucleotide promotes microglial cell uptake
of amyloid b 1-42 peptide by up-regulating the expression of the
G-protein-coupled receptor mFPR2. FASEB J 2005, 19:2032e2034
15. Chen K, Iribarren P, Hu J, Chen J, Gong W, Cho EH, Lockett S,
Dunlop NM, Wang JM: Activation of Toll-like receptor 2 on microglia
promotes cell uptake of Alzheimer disease-associated amyloid b pep-
tide. J Biol Chem 2006, 281:3651e3659
16. Michaud JP, Richard KL, Rivest S: MyD88-adaptor protein acts as a
preventive mechanism for memory deﬁcits in a mouse model of Alz-
heimer’s disease. Mol Neurodegener 2011, 6:5
17. Tan J, Town T, Crawford F, Mori T, DelleDonne A, Crescentini R,
Obregon D, Flavell RA, Mullan MJ: Role of CD40 ligand inajp.amjpathol.org - The American Journal of Pathology
MyD88 and Alzheimer-Like Diseaseamyloidosis in transgenic Alzheimer’s mice. Nat Neurosci 2002, 5:
1288e1293
18. Town T, Laouar Y, Pittenger C, Mori T, Szekely CA, Tan J, Duman RS,
Flavell RA: Blocking TGF-beta-Smad2/3 innate immune signaling
mitigates Alzheimer-like pathology. Nat Med 2008, 14:681e687
19. Johnson-Wood K, Lee M, Motter R, Hu K, Gordon G, Barbour R,
Khan K, Gordon M, Tan H, Games D, Lieberburg I, Schenk D,
Seubert P, McConlogue L: Amyloid precursor protein processing and
a-beta(42) deposition in a transgenic mouse model of Alzheimer dis-
ease. Proc Natl Acad Sci U S A 1997, 94:1550e1555
20. Kayed R, Glabe CG: Conformation-dependent anti-amyloid oligomer
antibodies. Methods Enzymol 2006, 413:326e344
21. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW,
Glabe CG: Common structure of soluble amyloid oligomers implies
common mechanism of pathogenesis. Science 2003, 300:486e489
22. Lee S, Varvel NH, Konerth ME, Xu G, Cardona AE, Ransohoff RM,
Lamb BT: CX3CR1 deﬁciency alters microglial activation and reduces
beta-amyloid deposition in two Alzheimer’s disease mouse models.
Am J Pathol 2010, 177:2549e2562The American Journal of Pathology - ajp.amjpathol.org23. Liu Z, Condello C, Schain A, Harb R, Grutzendler J: CX3CR1 in
microglia regulates brain amyloid deposition through selective proto-
ﬁbrillar amyloid-b phagocytosis. J Neurosci 2010, 30:17091e17101
24. Liu Y, Walter S, Stagi M, Cherny D, Letiembre M, Schulz-
Schaeffer W, Heine H, Penke B, Neumann H, Fassbender K: LPS
receptor (CD14): a receptor for phagocytosis of Alzheimer’s amyloid
peptide. Brain 2005, 128:1778e1789
25. Fiala M, Liu P, Espinosa-Jeffery A, Rosenthal M, Bernard G,
Ringman J, Sayre M, Zhang L, Zaghi J, Dejbakhsh S, Chiang B, Hui J,
Mahanian M, Baghaee A, Hong P, Cashman J: Innate immunity and
transcription of MGAT-III and Toll-like receptors in Alzheimer’s
disease patients are improved by bisdemethoxycurcumin. Proc Natl
Acad Sci U S A 2007, 104:12849e12854
26. Landreth GE, Reed-Geaghan EG: Toll-like receptors in Alzheimer’s
disease. Curr Top Microbiol Immunol 2009, 336:137e153
27. Lim JE, Song M, Jin J, Kou J, Pattanayak A, Lalonde R, Fukuchi K:
The effects of MyD88 deﬁciency on exploratory activity, anxiety,
motor coordination, and spatial learning in C57BL/6 and APPs-
we/PS1dE9 mice. Behav Brain Res 2012, 227:36e422861
